VTV Therapeutics (VTVT)

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. Additionally, vTv is developing TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonist that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis-related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. The company is also developing HPP737, an orally administered non-central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. vTv Therapeutics has a license agreement with Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.